Skip to main content

Table 2 Clinical studies of COVID-19 in CF

From: Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic

Citation Countries reporting Sample size (n) Study design Main findings
Cosgriff et al. [18] Australia, Canada, France, Ireland, Netherlands, New Zealand, UK, USA 40 Multinational cohort observational Incidence of COVID-19 in CF was 0.07%, compared to 0.15% in general population
     Clinical features of COVID-19 similar in CF and general population
     No deaths in cohort
McClenaghan et al. [19] Argentina, Australia, Belgium, Brazil, Canada, Chile, France, Germany, Ireland, Italy, Netherlands, New Zealand, Russia, South Africa, Spain, Sweden, Switzerland, UK, and USA 181 Multinational cohort observational Post-transplant individuals (18%) and FEV1 < 70% were hospitalized at significantly higher rates
     7 deaths in cohort (3 post-transplant)
Corvol et al. [20] France 31 Prospective cohort Incidence of COVID-19 in CF was 0.41%, 93% less than general population
     Post-transplant individuals (39%) received supplemental oxygen and were hospitalized at significantly higher rates
     No deaths in cohort
Mondejar-Lopez et al. [21] Spain 8 Retrospective descriptive cohort Incidence of COVID-19 in CF was 0.32%, compared to 0.49% in general Spanish population
     Pediatric subset was not hospitalized, but all adults were
     No deaths in cohort
Bain et al. [22] Argentina, Brazil, Chile, France, Germany, Italy, Russia, South Africa, Spain, Sweden, Switzerland, UK, US 105 Multinational cohort observational 29% asymptomatic
     FEV1 of hospitalized children significantly lower than non-hospitalized
     No deaths directly attributed to COVID-19 in cohort
Moeller et al. [23] N/Aa 14 Survey 7 individuals (50%) were hospitalized, with 3 in the PICU
     No deaths in sample
  1. CF cystic fibrosis, FEV1 forced expiratory volume in 1 s, PICU pediatric intensive care unit, UK United Kingdom, USA Unites States of America.
  2. aThe survey stratified patients by asthma, cystic fibrosis, bronchopulmonary dysplasia, and other respiratory conditions but did not specify the number of countries for each condition